Drug Profile
Fenretinide intravenous - CerRx
Alternative Names: 4-HPR – CerRxLatest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Ortho-McNeil Pharmaceutical
- Developer CerRx; South Plains Oncology Consortium
- Class Antineoplastics; Antivirals; Chemopreventatives; Retinoids; Small molecules
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Peripheral T-cell lymphoma; Solid tumours
- No development reported Lymphoma
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for phase-I development in Lymphoma(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, In adults) in USA (IV, Infusion)
- 28 Jan 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, In adults) in USA (IV, Infusion)
- 28 Jan 2022 No recent reports of development identified for phase-I development in Solid-tumours(In adolescents, In children, In infants, In neonates) in USA (IV, Infusion)